Table 4 Number of infusion reactions classified according to grade of seriousness
From: Predictors of infusion reactions during infliximab treatment in patients with arthritis
Group | Grade of seriousness | Infusion reactions | ||||
|---|---|---|---|---|---|---|
All | Infliximab dosage unchanged | Infliximab dosage increased at 3–6 months | Infliximab dosage increased at 6–12 months | Infliximab dosage increased at 12 months | ||
RA patients (n = 45) | Life threatening | 2 | 1 | 1 | 0 | 0 |
Serious | 16 | 11 | 2 | 1 | 2 | |
Moderate | 24 | 15 | 8 | 5 | 6 | |
Mild | 3 | 1 | 0 | 1 | 1 | |
SpA patients (n = 10) | Life threatening | 0 | 0 | 0 | 0 | 0 |
Serious | 6 | 4 | 1 | 1 | 0 | |
Moderate | 2 | 1 | 1 | 0 | 0 | |
Mild | 2 | 1 | 1 | 1 | 0 | |